Spots Global Cancer Trial Database for Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating HPV

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating HPV

Official Title: Conducting an Early Phase Clinical Trial to Assess for HPV Antigen Presentation Therapeutic Biological Product Mix Activity That Suggests the Potential for Clinical Benefits of HPV Patients.

Study ID: NCT02403505

Conditions

HPV Infection

Interventions

9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use

Study Description

Brief Summary: Conducting an early phase clinical trial to assess HPV Antigen Presentation Therapeutic Biological Product Mix activity that suggests the potential for clinical benefit of HPV patients. 1. Treat Infection of Multiple HPV Virus Strains via Trained Immunity. 2. Activate human HPV Antigen Presentation Reaction. 3. The human antigen presenting cells (APCs) can treat the HPV virus protein antigens into small peptide fragments, and then clear HPV virus in vivo.

Detailed Description: * Conducting an early phase clinical trial to assess HPV Antigen Presentation Therapeutic Biological Product Mix activity that suggests the potential for clinical benefit of HPV patients * 20 Cervical HPV Infection Patients * Positive testing HPV by standard PCR assay * HPV infection without symptoms * No clinical signs indicative of oncology * PPD negative participant is 10 TU skin test reading \< 5 mm induration at 48 hours * Our trial duration will be 12-week duration. * 9vHPV Vaccine 1.0 mL plus BCG Organism 50 MG Mix * By the percutaneous route with the multiple puncture device * Our trial duration will be 12-week duration * Negative testing HPV by standard PCR assay after percutaneous 21 days